Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked ...

In July, the Summer Law and Trial Institute (SLTI) welcomed 24 high school students from across the state of Ohio both to Athens and to the practice of law. OHIO's faculty and staff, across various ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

The world's largest music company laid out a vision to drive revenue growth through 2028. The FTC report said the companies responsible for controlling spending on drugs were sometimes steering ...

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

New data from cancer screening and diagnostic test provider Exact Sciences have shown an 88.3% sensitivity rate for its blood-based colorectal cancer screening test.

A study tracks how the structure of the brain changes during pregnancy, drawing on brain scans gathered before, during and ...